ネブラスカ州における頭頸部扁平上皮癌の臨床試験
ネブラスカ州内の拠点で、頭頸部扁平上皮癌に関する15件の研究が参加者を募集しています。
ネブラスカ州内の都市
公式研究テキスト（英語）
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
- Nebraska Medicine-Bellevue, Bellevue
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06992427Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #2, Omaha
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Nebraska Cancer Specialists, Omaha
- XCancer, Omaha
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07189871BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Nebraska Medicine-Bellevue, Bellevue
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05136196A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- NHO Revive Research Institute, LLC, Lincoln
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07276399Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- Nebraska Methodist Hospital, Omaha
被験者募集中第2相
18歳〜79歳 · 全性別 · 2026/09/22更新 · NCT04671667A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Nebraska Cancer Specialists, Omaha
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07109726Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- CHI Health Saint Francis, Grand Island
- CHI Health Good Samaritan, Kearney
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- 他4件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT02734537A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06769698Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- Nebraska Methodist Hospital, Omaha
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT04333537Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Nebraska Cancer Specialists, Omaha
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/29更新 · NCT04198766Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399, Omaha
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT05005403A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Omaha
被験者募集中第3相
18歳以上 · 全性別 · 2026/05/26更新 · NCT06256588DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA14-0, Lincoln
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/22更新 · NCT06953089Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Nebraska Cancer Specialists, Omaha
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/02/18更新 · NCT07030257ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。